Fairvalue-Calculator Fairvalue-Calculator
EN DE

Pharmigene, Inc (7595) Fair Value & Analysis

Healthcare · TW · Market cap 411M TWD

Price7.44 TWD
Fair Value3.70 TWD
Upside-50.3%
Quality95/100
Evidence: Low Range 2.76 TWD – 5.52 TWD

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Pharmigene, Inc (7595) currently trades at 7.44 TWD, while our model-based Fair Value estimate is 3.70 TWD — implying the stock looks roughly 50.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test, and functional medicine test services. In addition, it distributes various genomics and genetics equipment and reagents; and provides professional consultation, training program, analysis software, and technical support solutions. Further, the company offers CDMO services. The company was founded in 1994 and is headquartered in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -96% Danaher Corporation (DHR) -52% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -66% Lonza Group (LZAGY) -59% Agilent Technologies, Inc (A) -54%

Frequently asked questions

Is Pharmigene, Inc (7595) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 3.70 TWD versus a price of 7.44 TWD — about −50% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 7595?
Our 21-model fair value for Pharmigene, Inc is 3.70 TWD (as of Jun 25, 2026), built from audited fundamentals. The current price is 7.44 TWD.
What is the quality score of 7595?
Pharmigene, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.